The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James) | Strategic Alliance Partners

May 16, 2024

Samilia Obeng-Gyasi, MD, MPH, discusses a retrospective study on neighborhood opportunity and all-cause mortality in patients with breast cancer.

May 15, 2024

Samilia Obeng-Gyasi, MD, MPH, highlights a study on the association between neighborhood opportunity with all-cause mortality in patients with breast cancer.

May 08, 2024

Laura J Chambers, DO, discusses currently approved PARP inhibitors that are considered for use in ovarian cancer.

May 08, 2024

Casey M. Cosgrove, MD, discusses the FDA approval of mirvetuximab soravtansine for adult patients with Frα+, platinum-resistant ovarian cancer.

April 25, 2024

Raj Singh, MD, discusses unmet medical needs in the treatment of patients with lung cancer.

April 23, 2024

Raj Singh, MD, discusses the use of stereotactic body radiation therapy and stereotactic radiosurgery in the treatment of patients with lung cancer.

April 16, 2024

Margaret E. Gatti-Mays, MD, MPH, FACP, discusses the current use of neoadjuvant chemoimmunotherapy in early-stage triple-negative breast cancer.

April 06, 2024

Samilia Obeng-Gyasi, MD, MPH, discusses breast cancer mortality rates in resource-poor neighborhoods.

March 28, 2024

Raj Singh, MD, discusses treating patients with lung cancer with CNS metastases.

March 16, 2024

Quad Shot radiation plus a checkpoint inhibitor significantly improved local control vs Quad Shot alone and was well tolerated as a palliative treatment for patients with advanced head and neck cancer.

March 01, 2024

Samilia Obeng-Gyasi, MD, MPH, discusses the impact of social determinants of health on breast cancer care outcomes.

February 29, 2024

The panel provides advice for community providers treating patients with chronic GVHD, stressing effective communication, staying updated on evolving drugs, and collaborating with specialized multidisciplinary groups for optimal patient care.

February 29, 2024

The expert doctors discuss the impact of chronic GVHD on long-term survivors' quality of life (QoL). The panel explores the significance of patient-reported outcomes (PROs), challenges in their implementation, and the evolving role of PROs in assessing and improving QoL in chronic GVHD patients.

February 26, 2024

Dr Mims discusses the utility of emavusertib in acute myeloid leukemia and myelodysplastic syndrome and the rationale for the TakeAim Leukemia trial.

February 22, 2024

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz share their predictions for the next 3 to 5 years in chronic GVHD management. The panel anticipates advancements in earlier treatment, potential elimination of frontline corticosteroids, and a shift towards preventive strategies and personalized medicine.

February 22, 2024

The panel reviews axatilimab, an emerging agent for chronic GVHD under clinical studies. The experts explore findings from the Agave-201 study, highlighting potential challenges of intravenous administration and axatilimab’s unique mechanisms.

February 15, 2024

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz discuss a complex chronic GVHD case post-allogeneic transplant. The panel explores third-line options, including belumosudil, ibrutinib, photopheresis, and clinical trials, emphasizing shared decision-making and the need for well-designed trials in guiding treatment decisions.

February 15, 2024

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz review a clinical scenario of chronic GVHD post-allogeneic transplant. They explore treatment options and emphasize shared decision-making, considering patient preferences and therapeutic benefits.

February 12, 2024

Alice Mims, MD, discusses the toxicity profile and initial efficacy of emavusertib in heavily pretreated, FLT3-mutated relapsed/refractory AML.

February 08, 2024

The expert panel explores belumosudil's role in treating chronic GVHD after multiple systemic therapy lines. They discuss the ROCKstar trial, highlighting its overall response rates and real-world experiences.